ARCHIVES

Phase III Trial of Alimta, Avastin Combination Fails Endpoint to Improve Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 9 | September 28, 2012

Download PDF Visit The Full Archive

Related Articles

Von Eschenbach says oncology is undergoing a “revolutionary evolution.”

May 20, 2005

Genentech Reps Not Welcome: Hospitals Urge Drug Maker to Reverse Policy On Supplying Avastin, Rituxan, & Herceptin

October 17, 2014

Avon 1995 Grant Application Available

December 2, 1994

Grant Applications Pour Into NCI, NIH; Downward Trend In Funding Due To Be Reversed In FY 1979

June 16, 1978

Sorafenib Targets AML Driven By Mutant FLT3 Gene

February 29, 2008

AACR Elion Award Deadline Is Jan. 10

September 16, 1994